NLRP3 and Alzheimer disease: Directly targeting AMPK may lead to unintended consequences, highlighting the need to carefully consider whether modulating upstream regulators or downstream pathways—such as autophagy and NLRP3 inflammasome activation—offers a more viable therapeutic strategy for AD.